Descombes Eric, Fellay Benoit, Hemett Ould Maouloud, Magnin Jean-Luc, Fellay Gilbert
Service of Nephrology, HFR Hôpital Cantonal, 1708 Fribourg, Switzerland.
Central Laboratory, HFR Hôpital Cantonal, 1708 Fribourg, Switzerland.
Int J Nephrol. 2014;2014:597429. doi: 10.1155/2014/597429. Epub 2014 Jan 21.
The aim of the present study was to evaluate the dose of postdialysis cholecalciferol needed to maintain the 25-hydroxyvitamin D [25(OH)D] levels in the optimal range of 75-150 nmol/L. Twenty-six patients who had low baseline 25(OH)D levels (mean 27.5 ± 14.9 nmol/L) were studied. The 25(OH)D levels were measured every 2 months for one year. During the first two months, all the patients received 2000 IU of cholecalciferol after each hemodialysis (=6000 IU/wk). Thereafter, the dose was individualized and adapted every 2 months by administering 1 to 6 cholecalciferol tablets (2000 IU each) per week (total weekly dose = 2000-12000 IU/wk). During cholecalciferol supplementation, the 25(OH)D concentrations rapidly increased from baseline to 140.1 ± 28.3 nmol/L at month 6 and 95.6 ± 20.9 nmol/L at month 12. At month twelve, 86% of the patients had 25(OH)D levels within the target range with a mean dose of 5917 ± 4106 IU/wk of cholecalciferol; however, the amount needed to maintain these levels varied widely from 0 (n = 2) to 12000 IU/wk (n = 5). In conclusion, postdialysis cholecalciferol prescription is quite effective in correcting vitamin D deficiency/insufficiency, but the amount of cholecalciferol needed to maintain the 25(OH)D levels within the optimal range over the long-term varies widely among patients and must be individualized.
本研究的目的是评估维持25-羟基维生素D[25(OH)D]水平在75-150 nmol/L最佳范围内所需的透析后胆钙化醇剂量。对26例基线25(OH)D水平较低(平均27.5±14.9 nmol/L)的患者进行了研究。一年内每2个月测量一次25(OH)D水平。在最初的两个月里,所有患者每次血液透析后接受2000 IU胆钙化醇(=6000 IU/周)。此后,每2个月根据个体情况调整剂量,每周服用1至6片胆钙化醇片(每片2000 IU)(每周总剂量=2000-12000 IU/周)。在补充胆钙化醇期间,25(OH)D浓度从基线迅速升高,第6个月时达到140.1±28.3 nmol/L,第12个月时为95.6±20.9 nmol/L。在第12个月时,86%的患者25(OH)D水平在目标范围内,胆钙化醇的平均剂量为5917±4106 IU/周;然而,维持这些水平所需的剂量差异很大,从0(n=2)到12000 IU/周(n=5)。总之,透析后胆钙化醇处方在纠正维生素D缺乏/不足方面相当有效,但长期维持25(OH)D水平在最佳范围内所需的胆钙化醇量在患者之间差异很大,必须个体化。